An open-label phase 2 study of glycogen synthase kinase-3 inhibitor LY2090314 in patients with acute leukemia
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
This open-label, Phase-2 study investigated the safety of LY2090314 (GSK-3 inhibitor) in AML patients. Twenty patients received 40-mg LY2090314 (50-mg ranitidine pretreatment) as follows: Cohort 1 - days 1, 8, and 15 of a 28-d cycle (n = 7); Cohort 2 - days 1, 5, and 9 of a 21-d cycle (n = 6); Cohort 3 - days 1, 5, 9, and 12 of a 21-d cycle (n = 7). Decreased appetite (n = 7) and nausea (n = 4) were the most frequently reported possibly drug-related non-hematologic treatment-emergent adverse events (TEAEs). Hematologic TEAEs included febrile neutropenia (n = 2), thrombocytopenia (n = 1), and anemia (n = 1). Atrial flutter (n = 1), QT interval prolongation (n = 3), and visual disturbances (n = 2) were observed, but were not clinically significant (investigator assessed). Although β-catenin levels indicated an on-target effect, no complete or partial remissions were observed. Pharmacokinetics were consistent with a previous Phase 1 study. These data suggest that single-agent LY2090314 has acceptable safety but limited clinical benefit in AML patients at the dose/frequencies investigated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GSK-3: tricks of the trade for a multi-tasking kinase
Doble, B. W., & Woodgett, J. R. (2003) · Journal of Cell Science · doi:10.1242/jcs.00384 · Cited by 2,084 · cited 1×
“cascade.[1,2] Data suggest that GSK-3 signaling may also be critically important in cancer.”
BackgroundGlycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy
Wang, Z., Smith, K. S., Murphy, M., Piloto, O., Somervaille, T. C. P., & Cleary, M. L. (2008) · Nature · doi:10.1038/nature07284 · Cited by 265 · cited 1×
“concept that GSK-3 inhibitors may represent a novel therapeutic alternative for the treatment of hematological malignancies.[4] LY2090314 is a potent and selective inhibitor of GSK3.”
Background
Cited by
Wnt/β-catenin signaling in cancers and targeted therapies
Yu, F., Yu, C., Li, F., Zuo, Y., Wang, Y., Yao, L., Wu, C., Wang, C., & Ye, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00701-5 · Cited by 734
“GSK3/inhibitor LY2090314 NCT01214603(440) (P2); NCT01287520(441) (P1); Rizzieri et al.(442); Gray et al.”
Molecular Pathways: Revisiting Glycogen Synthase Kinase-3β as a Target for the Treatment of Cancer
Walz, A., Ugolkov, A., Chandra, S., Kozikowski, A., Carneiro, B. A., O'Halloran, T. V., Giles, F. J., Billadeau, D. D., & Mazar, A. P. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2240 · Cited by 160
“The majority of the adverse events were of grade 1 severity, with only seven grade 3 events and one grade 4 event (57).”
BackgroundMethodInfluentialGSK-3 as a novel prognostic indicator in leukemia
Ruvolo, P. P. (2017) · Advances in Biological Regulation · doi:10.1016/j.jbior.2017.05.001 · Cited by 39
“A Phase II clinical trial with the GSK3 inhibitor LY2090314 has been performed in AML (Rizzieri et al., 2016).”
BackgroundJiang, M., Guo, R., Ai, Y., Wang, G., Tang, P., Jia, X., He, B., Yuan, Q., & Xie, X. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100670 · Cited by 13
Metadata
- Authors
- Rizzieri, D. A., Cooley, S., Odenike, O., Moonan, L., Chow, K. H., Jackson, K., Wang, X., Brail, L., & Borthakur, G.
- Venue
- Leukemia & Lymphoma
- Publisher
- Informa UK Limited
- Published
- 2016-01-06
- Volume
- 57
- Issue
- 8
- Pages
- 1800-1806
- ISSN
- 1026-8022 (ISSN-L)
- 1042-8194
- 1029-2403
- OpenAlex
- W2232534574
- Cited by
- 81
- References
- 2
- FWCI
- 5.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An open-label phase 2 study of glycogen synthase kinase-3 inhibitor LY2090314 in patients with acute leukemia. https://app.cochat.ai/papers/10.3109/10428194.2015.1122781
- The paper
- Rizzieri, D. A., Cooley, S., Odenike, O., Moonan, L., Chow, K. H., Jackson, K., Wang, X., Brail, L., & Borthakur, G. (2016). An open-label phase 2 study of glycogen synthase kinase-3 inhibitor LY2090314 in patients with acute leukemia. Leukemia & Lymphoma. https://doi.org/10.3109/10428194.2015.1122781
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.